Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for Vor Biopharma to a loss of $0.91 per share from $0.70, while maintaining a Buy rating and $31 price target.
• Vor Biopharma reported a quarterly loss of $0.80 per share, missing the $0.69 consensus estimate, and remains projected to post substantial losses through fiscal 2028 before reaching profitability in fiscal 2029.
• Despite the weaker earnings outlook, the stock rose 4.3% to $23.29, while analysts’ average rating remained Moderate Buy with a consensus price target of $43.38.

Vor Biopharma Inc. (NASDAQ:VOR - Free Report) - Analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Vor Biopharma in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.91) per share for the quarter, down from their prior forecast of ($0.70). HC Wainwright has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($2.64) per share. HC Wainwright also issued estimates for Vor Biopharma's Q4 2026 earnings at ($0.94) EPS, Q1 2027 earnings at ($0.74) EPS, Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.89) EPS, Q4 2027 earnings at ($0.92) EPS, FY2027 earnings at ($3.65) EPS, FY2028 earnings at ($2.61) EPS and FY2029 earnings at $1.33 EPS.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11).

VOR has been the topic of a number of other reports. Wall Street Zen cut shares of Vor Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Jefferies Financial Group upgraded Vor Biopharma to a "strong-buy" rating in a report on Thursday, April 30th. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a research report on Tuesday. Finally, Wedbush boosted their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $43.38.

Vor Biopharma Stock Up 4.3%

NASDAQ VOR opened at $23.29 on Friday. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $50.20. The company has a 50 day moving average of $18.36 and a 200-day moving average of $15.96.

Institutional Trading of Vor Biopharma

A number of institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new position in shares of Vor Biopharma in the 1st quarter worth $2,298,000. UBS Group AG lifted its stake in shares of Vor Biopharma by 284.8% in the fourth quarter. UBS Group AG now owns 292,118 shares of the company's stock valued at $3,821,000 after buying an additional 216,209 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in shares of Vor Biopharma during the fourth quarter worth about $33,275,000. NEXTBio Capital Management LP bought a new position in Vor Biopharma in the 4th quarter valued at about $13,080,000. Finally, Simplify Asset Management Inc. acquired a new position in Vor Biopharma during the 1st quarter valued at about $955,000. Institutional investors own 97.29% of the company's stock.

Key Headlines Impacting Vor Biopharma

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target for Vor Biopharma to $27 from $18, implying additional potential upside, although it maintained a Neutral rating. Wedbush Increases Vor Biopharma Price Target to $27
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $31 price target. Its forecasts also continue to anticipate a shift to profitability, including projected positive EPS of $1.33 in fiscal 2029 and $3.89 in fiscal 2030.
• Neutral Sentiment: The revised HC Wainwright estimates provide investors with updated expectations for Vor Biopharma’s clinical-development spending and path toward profitability. The company is still expected to report substantial losses in the near term, including fiscal 2027 EPS of ($3.65) and fiscal 2028 EPS of ($2.61).
• Negative Sentiment: Vor Biopharma’s latest quarterly loss was $0.80 per share, worse than the $0.69 analyst consensus, reinforcing concerns about higher-than-expected expenses and near-term cash needs.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026 to ($0.91) from ($0.70) and Q4 2026 to ($0.94) from ($0.72). It also lowered fiscal 2027 EPS to ($3.65) from ($2.78), fiscal 2028 to ($2.61) from ($1.67), fiscal 2029 to $1.33 from $1.86, and fiscal 2030 to $3.89 from $4.27. These cuts suggest profitability may arrive later or be weaker than previously expected.
• Negative Sentiment: The shares decreased 6.5% after the weak earnings report, indicating that investors are focusing more on the earnings miss and downward estimate revisions than on the bullish price targets. Vor Biopharma Stock Price Down Following Weak Earnings

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source